Pluri (PLUR) AI Stock Analysis

Pluri

(TASE:PLUR)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthStrong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.

Negative Factors

Financial InstabilityFinancial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.

Pluri (PLUR) vs. iShares MSCI Israel ETF (EIS)

Market Cap: ILS 13.38M
Dividend Yield: ―
Average Volume (3M): 12.48K
Price to Earnings (P/E): -0.5
Beta (1Y): 0.39
Revenue Growth: -33.81%
EPS Growth: 38.96%
Country: Israel
Employees: 92
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pluri Business Overview & Revenue Model

Company Description

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and h...

Pluri Risk Analysis

Pluri disclosed 45 risk factors in its most recent earnings report. Pluri reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Failure to meet Nasdaq's continued listing requirements could result in the delisting of our common shares, negatively impact the price of our common shares and negatively impact our ability to raise additional capital.Q1, 2025

2.Failure to reach an agreement with the EIB about the repayment of the EIB Loan could adversely affect our financial condition and liquidity.Q1, 2025

3.Our principal research, development and manufacturing facilities are located in Haifa, Israel and military conditions in Israel, including armed conflicts between Israel and Hamas, Hezbollah and other terrorist organizations from the Gaza Strip and Lebanon, may cause interruption or suspension of our business operations without warning.Q1, 2025

Pluri Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IL:PLUR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56Neutral	$109.48M	-3.64	-311.07%	―	―	61.30%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANTX	44Neutral	$170.95M	-4.23	-53.52%	―	―	13.97%
IGC	42Neutral	$21.49M	-2.25	-113.58%	―	―	―

* Healthcare Sector Average

Performance Comparison

IL:PLUR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IL:PLUR	Pluri Inc.	393.50	-836.50	-68.01%
IGC	Igc Pharma, Inc.	0.19	-0.20	-50.64%
PYPD	PolyPid Ltd.	5.42	1.58	41.15%
ANTX	AN2 Therapeutics, Inc.	4.35	3.21	281.58%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pluri AI Stock Analysis